Sign In
Buy BHVN
$10.81
+0.680 (+6.71%)
At Close: Jun 03, 2026
Biohaven Presents Expanded EEG and Safety Data for BHV-7000 at the American Epilepsy Society Annual Meeting
04:30pm, Friday, 01'st Dec 2023
Biohaven reported full results from the BHV-7000 Phase 1 study examining doses up to 120 mg daily, demonstrating BHV-7000 was well-tolerated at all doses studied without the typical central nervous sy
Is Biohaven Ltd. (BHVN) Outperforming Other Medical Stocks This Year?
11:17am, Thursday, 16'th Nov 2023
Here is how Biohaven Ltd. (BHVN) and Blueprint Medicines (BPMC) have performed compared to their sector so far this year.
Biohaven Ltd. (BHVN) Is a Great Choice for 'Trend' Investors, Here's Why
10:32am, Monday, 06'th Nov 2023
If you are looking for stocks that are well positioned to maintain their recent uptrend, Biohaven Ltd. (BHVN) could be a great choice.
Are Medical Stocks Lagging Biohaven Ltd. (BHVN) This Year?
11:21am, Tuesday, 31'st Oct 2023
Here is how Biohaven Ltd. (BHVN) and Blueprint Medicines (BPMC) have performed compared to their sector so far this year.
Here's Why Momentum in Biohaven Ltd. (BHVN) Should Keep going
10:33am, Thursday, 19'th Oct 2023
Biohaven Ltd. (BHVN) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move.
Biohaven (BHVN) Up on Positive Data from Autoimmune Disease Drug
09:01am, Thursday, 28'th Sep 2023
Biohaven (BHVN) gains on preliminary data from a pre-clinical study on its pipeline candidate BHV-1300 targeting various autoimmune diseases.
Why Biohaven Stock Is Skyrocketing Today
12:00pm, Wednesday, 27'th Sep 2023
Biohaven released a new investor presentation that featured encouraging information about drug candidate BHV-1300. The experimental drug showed promise in treating autoimmune diseases.
Why Biohaven Stock Is Crashing Today
12:50pm, Thursday, 27'th Jul 2023
The FDA refused to review Biohaven's filing for approval of troriluzole in treating an ultrarare disease. Biohaven still hopes to convince the agency of the merits of its data on the experimental drug
2 Growth Stocks With Major Incoming Catalysts
05:31am, Tuesday, 27'th Jun 2023
BridgeBio stock collapsed when acoramidis failed a pivotal trial, but follow-up data on the way could allow the program, and the stock, to redeem itself. Biohaven shares could shoot higher if the U.S.
Why Biohaven Stock Caught Fire This Week
09:11am, Friday, 02'nd Jun 2023
Wednesday, Biohaven held a research and development day presentation for investors. With the company making progress on several fronts, investors appear to be optimistic about its post-buyout future.
Biohaven (BHVN) Stock up 8% on Encouraging Pipeline Updates
12:36pm, Thursday, 01'st Jun 2023
At its R&D Day, Biohaven (BHVN) provides updates on its pipeline. It also announced submission of a regulatory filing seeking approval for troriluzole in SCA3, an ultra-rare disorder.
Is Biohaven Ltd. (BHVN) Stock Outpacing Its Medical Peers This Year?
11:23am, Thursday, 30'th Mar 2023
Here is how Biohaven Ltd. (BHVN) and Hologic (HOLX) have performed compared to their sector so far this year.
Biohaven (BHVN) Acquires Dual Inhibitor for Brain Disorders
12:13pm, Thursday, 23'rd Mar 2023
Biohaven (BHVN) has acquired an exclusive license for dual Inhibitor of TYK2/JAK1 for the pre-clinical study of immune-mediated brain disorders.
Biohaven: Spun And Done - Time To Exit
05:06pm, Thursday, 09'th Mar 2023
Biohaven is on the far side of its spin cycle and faces the world as a much diminished company. Biohaven has upcoming catalysts, but they are either early stage or have serious question marks.
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric
12:52pm, Thursday, 02'nd Feb 2023
Biohaven is taking the same tact that led to a nearly $12 billion Pfizer buyout with the rest of its pipeline — and BHVN stock has soared. The post Here's What's Next For Biohaven After Its $12 Bill
